These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 17637260)
21. Infrequent hypermethylation of WIF-1 promoter in BCR/ABL-negative myeloproliferative disorders. Suzuki R; Onizuka M; Kojima M; Shimada M; Tsuboi K; Ogawa Y; Kawada H; Ando K Tokai J Exp Clin Med; 2007 Dec; 32(4):131-5. PubMed ID: 21318952 [TBL] [Abstract][Full Text] [Related]
22. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568 [TBL] [Abstract][Full Text] [Related]
23. Oligonucleotide array CGH studies in myeloproliferative neoplasms: comparison with JAK2V617F mutational status and conventional chromosome analysis. Tefferi A; Sirhan S; Sun Y; Lasho T; Finke CM; Weisberger J; Bale S; Compton J; LeDuc CA; Pardanani A; Thorland EC; Shevchenko Y; Grodman M; Chung WK Leuk Res; 2009 May; 33(5):662-4. PubMed ID: 18937974 [TBL] [Abstract][Full Text] [Related]
24. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects. Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582 [TBL] [Abstract][Full Text] [Related]
25. Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders. Basquiera AL; Soria NW; Ryser R; Salguero M; Moiraghi B; Sackmann F; Sturich AG; Borello A; Berretta A; Bonafé M; Barral JM; Palazzo ED; García JJ Hematology; 2009 Dec; 14(6):323-30. PubMed ID: 19941738 [TBL] [Abstract][Full Text] [Related]
26. Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. Aboudola S; Murugesan G; Szpurka H; Ramsingh G; Zhao X; Prescott N; Tubbs RR; Maciejewski JP; Hsi ED Am J Surg Pathol; 2007 Feb; 31(2):233-9. PubMed ID: 17255768 [TBL] [Abstract][Full Text] [Related]
27. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis. Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192 [TBL] [Abstract][Full Text] [Related]
28. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study. Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441 [TBL] [Abstract][Full Text] [Related]
29. Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms. Chen X; Qi X; Tan Y; Xu Z; Xu A; Zhang L; Wang H Blood Cells Mol Dis; 2011 Jun; 47(1):67-71. PubMed ID: 21555228 [TBL] [Abstract][Full Text] [Related]
31. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF). Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893 [TBL] [Abstract][Full Text] [Related]
32. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis. Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908 [TBL] [Abstract][Full Text] [Related]
33. Prevalence of the JAK2-V617F mutation in Taiwanese patients with chronic myeloproliferative disorders. Lieu CH; Wu HS; Hon YC; Tsai WH; Yang CF; Wang CC; Lin YC; Shih CH; Hsu HC Intern Med J; 2008 Jun; 38(6):422-6. PubMed ID: 18336541 [TBL] [Abstract][Full Text] [Related]
34. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377 [TBL] [Abstract][Full Text] [Related]
35. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms. Guo H; Chen X; Tian R; Chang J; Li J; Tan Y; Xu Z; Ren F; Zhao J; Pan J; Zhang N; Wang X; He J; Yang W; Wang H PLoS One; 2015; 10(9):e0138250. PubMed ID: 26375990 [TBL] [Abstract][Full Text] [Related]
36. [JAK2V617F mutation and p-STAT5 protein expression in peripheral blood cells of patients with myeloproliferative neoplasm and their relations with clinical features]. Chen YX; Li Y; Zhang LY; Liu X; Shan NN Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1398-404. PubMed ID: 23257441 [TBL] [Abstract][Full Text] [Related]